Navigation Links
Life Sciences Venture Capital Investments Soar In Q2 To Highest Level Since 2007, According To The MoneyTree Report
Date:8/25/2014

NEW YORK, Aug. 25, 2014 /PRNewswire/ -- Venture capital (VC) funding for the Life Sciences sector, which includes Biotechnology and Medical Devices, reached $2.5 billion in 195 deals for the second quarter of 2014, according to a new report, "Biotech soars to record high," which includes data from the MoneyTree™ Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. While this quarter was the highest Life Sciences investment since the second quarter 2007, it was also the strongest second quarter since 1995, which is the earliest data recorded by the MoneyTree.

During the second quarter of 2014, VC funding for Life Sciences increased 25 percent in dollars invested, while the number of deals was flat compared to the same period last year. Dollars flowing into Life Sciences companies accounted for 19 percent of total VC dollars invested in Q2, compared to 28 percent in the second quarter of 2013. The decrease is due, in part, to the increase in the number of megadeals (investments of $100 million and more) occurring in the Software sector. The average deal size for Life Sciences companies was $12.8 million for the second quarter of 2014, an increase of 26 percent year-over-year and 35 percent quarter-over-quarter.

"The uptick in VC investing in Q2 is a direct reflection of the activity we're seeing in the public markets," said Greg Vlahos, Life Sciences Partner at PwC. "As VCs take advantage of the open initial public offering window and the high valuations in the mergers and acquisitions market to exit, they are putting capital back to work for a new cycle of investments. The competition for dollars among the next generation of life science businesses remains, and businesses looking to attract VC investment need to have comp
'/>"/>

SOURCE PwC US
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Telomere Biosciences Announces: TELO-20 for Dogs, the Worlds First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity
2. Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research
3. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
4. Leading ALS Researcher Joins the Kansas City University of Medicine and Biosciences
5. UAS LifeSciences to Donate to Women’s Non-Profit of Your Choice
6. Feist-Weiller Cancer Center Partners With Caris Life Sciences to Establish a Clinical Molecular Profiling Program
7. Regado Biosciences Announces Second Quarter 2014 Financial Results and Corporate Highlights
8. Alimera Sciences Reports Second Quarter 2014 Financial Results
9. Sangamo BioSciences Announces Presentation At The 2014 Wedbush Securities Life Sciences Management Access Conference
10. Ardelyx to Present at the Wedbush 2014 Life Sciences Management Access Conference
11. Neural ID Enables Auditing and Analysis of Biosignal Data Directly from the TIBCO Spotfire® Powerful Data Visualization Platform for PerkinElmer’s Life Sciences Customers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... THOUSAND OAKS, Calif. , May 27, 2015 /PRNewswire/ ... company, has been awarded a U.S. patent for a ... gene in areas such as research, product development and ... useful in regulating key biosynthetic processes that are the ... to offer other seed companies a commercial license to ...
(Date:5/26/2015)... OTTAWA, Canada, and BELLINGHAM, Washington, USA (PRWEB) May 26, ... has signed a formal partnership with the ... Ottawa Centre for Extreme and Quantum Photonics. The center ... in the field of photonics, and will be only ... Arthurs, CEO of SPIE, the international society for ...
(Date:5/26/2015)... and HILDEN, Germany , May ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... Clinical Insight ® (QCI™) bioinformatics content and ... and report on genomic variants identified in next-generation ... the bioinformatics platform are in oncology, for somatic ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Global ... have announced plans for the company’s first cellular and ... followed by a full day, hands-on stem cell training ... J. Victor Garcia Gimenez, M.D., President of Therapeutic Confrontations ... medical community’s increasing interest in regenerative medicine and recent ...
Breaking Biology Technology:Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3
... Adult Cough Products Using ... Technologies, CHESTER, N.J. and SALT LAKE CITY, Sept. ... and Lipocine Inc., a,privately- held, leading drug delivery company ... drug delivery and,therapeutics needs, today announced that they have ...
... Company Enters Into License, Commercialization and Supply Agreement, Company to Host Conference ... ... 2007, LEXINGTON, Mass., Sept. 19 ... AGN ), through its acquisition of Esprit Pharma, has obtained the,United States ...
... Kleiner Perkins ... Strong Endorsement of Technology Pioneer at Forefront of Developing No- ... Compromise Biofuels, ... hydrocarbon biofuels, today,announced that it closed the first tranche of its $70 million ...
Cached Biology Technology:Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement 2Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement 3Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6Amyris Biotechnologies Announces $70 Million Series B Round 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... therapy often harms healthy tissue as it tries to kill ... Department of Biomedical Engineering is developing a new way to ... surrounding tissue. His innovative method, soon to be ... kill the tumor cells but leaves surrounding healthy tissue intact. ...
... a leading cause of mortality worldwide, accounting for more than ... expected to exceed 12 million. The ESMO Congress provides a ... the treatment of cancer Congress Program Highlights ... potentially practice changing, Promising new drugs to treat ovarian, skin, ...
... Under the microscope, the bacteria start dividing normally, two ... then individual cells begin "popping," like circus balloons being struck ... bioengineers who captured it on video, turns out to be ... considered by scientists creating living, synthetic circuits out of bacteria. ...
Cached Biology News:A 'magnetic' solution to identify and kill tumors 235th ESMO Congress media alert 235th ESMO Congress media alert 3Popping cells surprise living circuits creators 2Popping cells surprise living circuits creators 3
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
... N.C. Price (1996) • This ... protein chemistry and the purification ... Data on the following procedures ... determination, amino acid analysis and ...
... Dunbar (1994) • This book describes ... methods for preparing samples for protein ... radiometric and bioluminescence-enhanced detection systems are ... the detection and characterization of glycoprotein ...
See product name for description....
Biology Products: